Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.
- Cytotoxic therapy
- Hormone-refractory prostate cancer
- Targeted therapy
ASJC Scopus subject areas
- Cancer Research